Overview
Isomorphic Labs, a drug-design company spun out of Alphabet, secured a $600 million Series A funding round in March 2025, led by Thrive Capital with participation from Google Ventures. The funding aims to revolutionize drug discovery using AI, addressing the inefficiencies of traditional methods that have a 90% failure rate in clinical trials. Partnerships with Eli Lilly and Novartis focus on tackling 'undruggable' diseases like pancreatic and lung cancers, although Isomorphic has yet to advance any drugs to clinical trials as of January 2026.
Products
Loading...
Recent Deals
Investors: Thrive Capital, Google Ventures
Isomorphic Labs, a drug-design company spun out of Alphabet, secured a $600 million Series A funding round in March 2025, led by Thrive Capital with participation from Google Ventures. The funding aims to revolutionize drug discovery using AI, addressing the inefficiencies of traditional methods that have a 90% failure rate in clinical trials. Partnerships with Eli Lilly and Novartis focus on tackling 'undruggable' diseases like pancreatic and lung cancers, although Isomorphic has yet to advance any drugs to clinical trials as of January 2026.